Berberine

Berberine has been studied in 406 papers since 1985: 89 trials and 3 observational studies in people, 73 in animals, 26 in cells, 207 reviews; 52 in the past year. The newest paper, Oct 31, 2026: “Selected Dietary and Supplemental Phytochemicals in Adiposity-Based Chronic Disease: Molecular Mechanisms, Human Evidence, and Translational Gaps”.

Intervention

406 papers study it7 more mention it424 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 58% faster than aging research as a whole: 11 papers in the latest year counted

More supplements

5 new papers in 30 daysSee all 246 papers on berberine

At a glance

Berberine extends lifespan in worms and flies, with independent replication in flies, although other experiments show no clear lifespan effect. A human trial reports reduced colorectal adenoma recurrence after polypectomy; independent labs reproduce LDL and total cholesterol reductions, although a human result shows no clear total cholesterol effect. Some papers have company-affiliated authors.

424 findings in 164 papers from 2003 to 2026, 14 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 80 independent labs in 16 countries; 43 trials, 1 about aging, 15 with no results posted.

“lower adenoma recurrence rate (34.7% vs. 52.1%)”
Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trialCell reports. Medicine2025doi:10.1016/j.xcrm.2025.102293

20 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 80 independent labs in 16 countries
  • 20 findings against
  • 43 trials, 1 about aging, 15 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 16 of 336 findings with company ties
  • Human trial58
  • Humans2
  • Animals33
  • Model organisms9
  • Cells7
  • In silico2

38 studies gave berberine to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on visceral adipose tissue area1.38% [97.5% CI, −2.43% to 5.18%]

no change: Has no effect on liver fat content0.87% [97.5% CI, −0.39% to 2.13%]

down: Decreases low-density lipoprotein cholesterol−7.72 [95% CI, −13.13 to −1.93] mg/dL

Randomized trial6 months337 people116 (34.4%) were female, and 221 (65.6%) were malemean (SD) age was 41.8 (10.6) yearsDiabetes-free individuals with obesity and MASLDJAMA network open, Jan 2, 2026

up: Increases VEGFA

down: Decreases pulse wave analysis systolic pressure134.85 ± 16.26 before and 124.46 ± 13.47 after

no change: Has no effect on arterial stiffness

Randomized trial12 weeks70 people40 to 60 yearsPatients with MAFLDNutrients, Nov 16, 2025

down: Decreases colorectal adenoma recurrenceadjusted HR 0.58, 95% CI 0.45–0.74

down: Decreases colorectal neoplasm occurrenceadjusted HR 0.75, 95% CI 0.62–0.91

Treated cohort2 years648 peoplePatients aged 18–75 years who had undergone endoscopic polypectomy six months before recruitmentCell reports. Medicine, Aug 11, 2025

down: Decreases homeostatic model assessment of insulin resistance0.51 ≤ ES ≤0.54

Randomized trial8 weeks64 peoplemenmiddle-agedMiddle-aged men with overweight or obesity and varying glycemic levelsPhysiological reports, Aug 1, 2024

down: Decreases alanine transaminasep=0.0105

down: Decreases de Ritis ratiop=0.0011

down: Decreases total cholesterolp=0.0009

Randomized trial12 weeks70 peopleMAFLDJournal of physiology and pharmacology : an official journal of the Polish Physiological Society, Jul 18, 2024

What did lifespan studies of berberine find?

DrugAge

DrugAge records 7 results from 3 papers: 5 in C. elegans, 1 in D. melanogaster and 1 in mice. Average lifespan is the mean or the median, as each paper reports it.

What did studies of berberine find?

210

Studies of berberine measured 210 outcomes; the most studied are inflammation (18 studies), LDL cholesterol (13) and body weight (13).

Inflammation

downin reviews7downin humans4downin mice4no changein humans1+2

18 studies
  1. Berberine inhibits inflammation in additive BBR-treated group compared with baseline levels.

    “The decrease of hsCRP in additive BBR‐treated group was significant (p < 0.05), whereas the decrease in hsCRP in the control group did not reach significance (p > 0.05; Figure b).”

    Human trialin additive BBR-treated group compared with baseline levels3 months

    Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways

    Phytotherapy research : PTR

  2. Berberine showed no clear effect on inflammation in humans.

    “Blood inflammatory factors (CRP, IL-6, TNFα, COX-2) and erythrocyte sedimentation rate (ESR) were not significantly affected by treatment with berberine.”

    Human trial12 weeks

    Lipid-lowering effect of berberine in human subjects and rats

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  3. Berberine decreases inflammation.

    “in adipose tissue, it attenuates adipogenesis, lipid accumulation and inflammation.”

    Reviewadipose tissue

    Effects of Berberine on Insulin-Sensitive Tissues: Nutrient-Derived Modulator of Metabolic Disease

    Cells

  4. Berberine inhibits inflammation in diverse clinical populations.

    “concurrent cardiometabolic and anti-inflammatory improvements”

    Reviewin diverse clinical populations

    The Integrative Role of Berberine in Gut Microbiota Modulation and Cardiometabolic Outcomes: A Systematic Review of Randomised Clinical Trials

    Nutrients

  5. Berberine decreases inflammation in ovariectomized mice.

    “This modulation led to the suppression of intestinal inflammation, evidenced by decreased expression of IL-1β, IL-6, IL-8, and TNF-α”

    Animalsin ovariectomized miceintestine100 mg/kg/day

    Berberine reshapes gut microbiota and attenuates bone loss in estrogen-deficient osteoporosis via the gut-bone axis

    Naunyn-Schmiedeberg's archives of pharmacology

  6. Berberine decreases inflammation in rats (HFD/STZ-induced diabetic nephropathy).

    “Furthermore, BHC-Lip or Vild treatments markedly reduced serum inflammatory cytokines”

    AnimalsHFD/STZ-induced diabetic nephropathy

    Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy

    Tissue & cell

  7. Berberine decreases inflammation in aged mice undergoing surgery and anaesthesia.

    “BBR markedly suppressed glial cell activation and reduced levels of pro-inflammatory cytokines such as tumour necrosis factor alpha (TNF-α) and interleukin-1 beta (IL-1β)”

    Animalsin aged mice undergoing surgery and anaesthesia10 mg/kg daily2 weeks

    Berberine Ameliorates Postoperative Cognitive Dysfunction in Aged Mice and Regulates the PI3K-AKT Pathway: A Network Pharmacology Study

    Journal of cellular and molecular medicine

  8. Berberine decreases inflammation.

    “Berberine exerts potent antibacterial, anti-inflammatory, and therapeutic effects in cardiovascular, neurological, metabolic, and tumor-related conditions by modulating key intracellular signaling pathways”

    Review

    Multiple target and regulatory pathways of berberine

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  9. Berberine decreases inflammation in atherosclerosis.

    “BBR reduced inflammation linked to SASP in atherosclerosis through the RXRα/PPARγ/NEDD4 signaling pathway.”

    Animalsin atherosclerosis

    Berberine Inhibited SASP-Related Inflammation through RXRα/PPARγ/NEDD4 Pathway in Atherosclerosis

    The American journal of Chinese medicine

  10. Berberine decreases inflammation in zebrafish (atorvastatin-induced intracerebral hemorrhage).

    “BBR was found to reduce brain inflammation and locomotion injury in ICH-zebrafish.”

    Animalsatorvastatin-induced intracerebral hemorrhage10, 50, and 100 μM

    Atorvastatin-induced intracerebral hemorrhage is inhibited by berberine in zebrafish

    Journal of applied toxicology : JAT

All 18

More on Inflammation

LDL cholesterol

downin humans12downin Cricetinae1downin reviews1−42% to −25%

13 studies
  1. Berberine decreases LDL cholesterol in humans (versus placebo) (-7.72 mg/dL [95% CI, -13.13 to -1.93]).

    “Berberine was associated with larger reductions in low-density lipoprotein cholesterol (-7.72 [95% CI, -13.13 to -1.93] mg/dL)”

    Human trialversus placebo1 g/d6 monthsn = 337

    Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial

    JAMA network open

  2. Berberine decreases LDL cholesterol in humans (compared with placebo).

    “Berberine reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol after 3 months from randomization and compared with placebo.”

    Human trialcompared with placebo500 mg twice a day3 months

    Effects of berberine on lipid profile in subjects with low cardiovascular risk

    Expert opinion on biological therapy

  3. Berberine decreases LDL cholesterol in humans (compared with ezetimibe in hypercholesterolemic subjects) (-31.7% vs -25.4% with ezetimibe, P < 0.001).

    “the nutraceutical pill resulted more effective than EZE in lowering LDL cholesterol (-31.7% vs -25.4%, P < 0.001)”

    Human trialcompared with ezetimibe in hypercholesterolemic subjectsnutraceutical pill

    Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

    Lipids in health and disease

  4. Berberine decreases LDL cholesterol in monotherapy.

    “The comparison of the two treatments in terms of percent lipid variations showed that BBR/P/RR was more effective than EZE in reducing TC, LDL-C and non-HDL-C levels, and showed a tendency to lower TG more than EZE.”

    Human trialin monotherapysix months

    Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment

    Lipids in health and disease

  5. Berberine decreases LDL cholesterol in humans (poorly controlled type 2 diabetes mellitus) (decreased significantly).

    “Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well.”

    Human trialpoorly controlled type 2 diabetes mellitus3 monthsn = 48

    Efficacy of berberine in patients with type 2 diabetes mellitus

    Metabolism: clinical and experimental

  6. Berberine decreases LDL cholesterol in type 2 diabetic patients with dyslipidemia (from 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, P < 0.0001 vs placebo).

    “low-density lipoprotein-cholesterol from 3.23 +/- 0.81 to 2.55 +/- 0.77 mm/liter, with all parameters differing from placebo significantly (P < 0.0001”

    Human trialin type 2 diabetic patients with dyslipidemia1.0 g daily3 monthsn = 116

    Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine

    The Journal of clinical endocrinology and metabolism

  7. Berberine decreases LDL cholesterol in humans (20% reduction).

    “BERB and COMB significantly reduced TC (respectively by 16% and 20%), LDL (by 20% and 25%), ApoB (by 15% and 29%) and TG (by 22% and 26%)”

    Human trial4 weeksn = 20

    Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation

    Arzneimittel-Forschung

  8. Berberine decreases LDL cholesterol in humans (hypercholesterolemia) (-25%).

    “Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%.”

    Human trialhypercholesterolemiaoral3 monthsn = 32

    Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

    Nature medicine

  9. Berberine decreases LDL cholesterol in humans (versus control) (MD -14.98 mg/dL [95%CI: -20.67 to -9.28]).

    “Berberine containing products significantly reduced TC (MD -17.42 mg/dL [95%CI: -22.91 to -11.93]), LDL (MD -14.98 mg/dL [95%CI: -20.67 to -9.28])”

    Reviewversus controlberberine-containing products8-18 wkn = 4,838

    Impact of Berberine or Berberine Combination Products on Lipoprotein, Triglyceride and Biological Safety Marker Concentrations in Patients with Hyperlipidemia: A Systematic Review and Meta-Analysis

    Journal of dietary supplements

  10. Berberine decreases LDL cholesterol in humans (-0.46 mmol/L (95% CI -0.62 to -0.30)).

    “Berberine reduced LDL cholesterol (- 0.46 mmol/L, 95% CI - 0.62 to - 0.30, 14 studies, n = 1447)”

    Review4 to 24 weeksn = 1,447

    Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Drugs

All 15

More on LDL cholesterol

Body weight

downin humans10upin mice1no changein mice1downin reviews1

13 studies
  1. Berberine decreases body weight in humans.

    “BBR significantly decreased (p < 0.05) body weight, blood pressure and Vis and Ap gene expression”

    Human trial3 months

    Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study

    Nutrients

  2. Berberine decreases body weight in humans (people living with HIV under virological suppression and metabolic syndrome).

    “The berberine group showed a reduction in weight and body mass index, lower insulin resistance, and a reduction in TNF-alpha.”

    Human trialpeople living with HIV under virological suppression and metabolic syndrome500 mg TID20 weeks

    Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection

    International journal of STD & AIDS

  3. Berberine decreases body weight in humans (schizophrenia spectrum disorders with metabolic syndrome) (MD -1.08, 95% CI -1.76 to -0.40, P = 0.002, d = 0.59).

    “Compared with the placebo group, the berberine group showed a significantly greater reduction in weight gain at 9 weeks (mean difference [MD], -0.75; 95% CI, -1.42 to -0.07 [P = 0.031, d = 0.41]) and 12 weeks (MD, -1.08; 95% CI, -1.76 to -0.40 [P = 0.002, d = 0.59]).”

    Human trialschizophrenia spectrum disorders with metabolic syndrome600 mg/d12 weeksn = 113

    Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial

    Psychiatry and clinical neurosciences

  4. Berberine decreases body weight in patients with schizophrenia on stable antipsychotic treatment (-1.10 kg vs +1.45 kg, P = 0.001).

    “At the 8th week, the mean weight of patients in the berberine group (N = 27) lost 1.10 kg, while in the placebo group (N = 22) gained 1.45 kg.”

    Human trialin patients with schizophrenia on stable antipsychotic treatment900 mg per day8-weekn = 49

    Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin

    Asian journal of psychiatry

  5. Berberine decreases body weight in humans (mildly overweight patients with non-alcoholic fatty liver disease).

    “reduced body weight, and improved insulin sensitivity in mildly overweight patients with non-alcoholic fatty liver disease”

    Human trialmildly overweight patients with non-alcoholic fatty liver disease1 month

    Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans

    Cell death & disease

  6. Berberine decreases body weight (-4.29(-5.04 –-3.54)kg vs -1.99(-2.76 –-1.23)kg).

    “In comparison with LSI alone, BBR exhibited extra decreases in body weight [-4.29(-5.04 –-3.54)kg vs -1.99(-2.76 –-1.23)kg, p<0.001”

    Human trial16-weeksn = 184

    Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

    PloS one

  7. Berberine decreases body weight in humans (plus LSI) (p<0.05).

    “paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05).”

    Human trialplus LSI0.5g tid16 weeks

    Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

    PloS one

  8. Berberine decreases body weight in humans (obese) (average 5 lb/subject).

    “The results demonstrate that berberine treatment produced a mild weight loss (average 5 lb/subject) in obese human subjects.”

    Human trialobese500 mg orally three times a day12 weeks

    Lipid-lowering effect of berberine in human subjects and rats

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  9. Berberine decreases body weight in humans (−0.88 kg (95% CI −1.36 to −0.39)).

    “−0.88 kg (−1.36 to −0.39) for berberine.”

    Review

    Selected Dietary and Supplemental Phytochemicals in Adiposity-Based Chronic Disease: Molecular Mechanisms, Human Evidence, and Translational Gaps

    Nutrients

  10. Berberine decreases body weight in humans (MD -0.88 kg, 95% CI -1.36 to -0.39).

    “Berberine significantly reduced body weight (MD of -0.88 kg, 95% CI: -1.36 to -0.39, p = 0.0003)”

    Review

    The effect of berberine on obesity indices: a systematic review and meta-analysis

    International journal of obesity (2005)

All 14

Total cholesterol

downin humans11downin hamsters1no changein humans1

13 studies
  1. Berberine decreases total cholesterol in humans (MAFLD) (p=0.0009).

    “a significant divergence between the BBR and placebo groups was evident in the alteration of Δ total cholesterol (TC) p=0.0009, favoring the BBR group”

    Human trialMAFLDoral1500 mg/day12 weeksn = 70

    Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial

    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society

  2. Berberine decreases total cholesterol in overweight subjects with impaired fasting blood glucose, versus placebo (β=-0.25 (95% CI -0.45; -0.04), p=0.05).

    “total cholesterol [β=-0.25, 95% C.I. (-0.45; -0.04), p=0.05]”

    Human trialin overweight subjects with impaired fasting blood glucose, versus placebophytosome (phospholipid complex)2 tablets/day, 550 mg/tablettwo monthsn = 49

    Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial

    European review for medical and pharmacological sciences

  3. Berberine decreases total cholesterol in humans (schizophrenia spectrum disorders with metabolic syndrome) (MD -0.58, 95% CI -0.74 to -0.41, P < 0.001, d = 1.31).

    “Patients who received berberine also showed statistically significant improvements in end point in body mass index (MD, -0.41; 95% CI, -0.65 to -0.17 [P = 0.001, d = 0.64]), total cholesterol (MD, -0.58; 95% CI, -0.74 to -0.41 [P < 0.001, d = 1.31]), low-density lipoprotein (MD, -0.52; 95% CI, -0.68 to -0.35 [P < 0.001, d = 1.19]), and glycated hemoglobin (MD, -0.09; 95% CI, -0.18 to 0 [P = 0.05, d = 0.37]).”

    Human trialschizophrenia spectrum disorders with metabolic syndrome600 mg/d12 weeksn = 113

    Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial

    Psychiatry and clinical neurosciences

  4. Berberine decreases total cholesterol in humans.

    “After 12 weeks of intervention, men taking berberine had a larger reduction in total cholesterol and HDL-c than those taking placebo.”

    Human trial12 weeksmalesn = 84

    Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial

    Nutrients

  5. Berberine decreases total cholesterol in humans (-0.39 mmol/L, 95% CI -0.70 to -0.08).

    “Men randomized to berberine had larger reductions in total cholesterol (-0.39 mmol/L, 95% confidence interval (CI) -0.70 to -0.08) and high-density lipoprotein cholesterol (-0.07 mmol/L, 95% CI -0.13 to -0.01) after 12 weeks.”

    Human trial500 mg orally, twice a day12 weeksmalesn = 80

    Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial

    Nutrients

  6. Berberine decreases total cholesterol in humans (adjunctive treatment) (all p<0.05).

    “Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”

    Human trialadjunctive treatment900mg/day8 weeksn = 49

    The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

    Psychiatry research

  7. Berberine decreases total cholesterol in humans (mixed dyslipidemia).

    “BBR reduced TC levels.”

    Human trialmixed dyslipidemiaoral500 mg t.i.d.90 daysn = 12

    Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial

    Journal of medicinal food

  8. Berberine decreases total cholesterol in humans (mild hyperlipidemia).

    “TG, TC, and LDL-C all decreased, and HDL-C increased in the treatment group (all P < 0.05).”

    Human trialmild hyperlipidemia300 mg thrice per day3 successive months

    Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia

    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

  9. Berberine decreases total cholesterol in humans (new diagnosed type 2 diabetes combining nonalcoholic fatty liver disease).

    “ALT, AST, TC, TG, LDL-L, hemorrheology (including the whole blood viscosity, whole blood viscosity, high cutting reduction of whole blood viscosity, plasma cutting reductive low viscosity, blood sedimentation, RBC deposited, fibrinogen) were significantly lower than before”

    Human trialnew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease12 weeks

    Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease

    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

  10. Berberine showed no clear effect on total cholesterol in humans (compared to routine or statins) (SMD 0.43, 95% CI -0.39 to 1.24).

    “There were no differences between berberine alone and routine or statins in improving total cholesterol (TC) (SMD, 0.43; 95% CI, -0.39 to 1.24; p = 0.30; I2 = 95%)”

    Reviewcompared to routine or statins

    Efficacy and safety of berberine for several cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials

    Phytomedicine : international journal of phytotherapy and phytopharmacology

All 14

More on Total cholesterol

HOMA-IR

downin humans9

9 studies
  1. Berberine decreases HOMA-IR in humans (berberine alone versus baseline).

    “Notably, there was a significant reduction in FBG and HOMA-IR with the BBR group compared to the baseline.”

    Human trialberberine alone versus baselineapproximately 1000 mg dailymales

    Inflammatory markers and noncoding-RNAs responses to low and high compressions of HIIT with or without berberine supplementation in middle-aged men with prediabetes

    Physiological reports

  2. Berberine decreases HOMA-IR in humans (2.41 ± 0.14 vs 3.40 ± 0.28 units).

    “HOMA-IR showed a similar significant reduction for the treatment group with mean values after 84 days at 2.41 ± 0.14 units compared to the control group mean values at 3.40 ± 0.28 (p<10− 5), as shown in Table.”

    Human trial84 daysn = 34

    Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

    BMC endocrine disorders

  3. Berberine decreases HOMA-IR in humans (prediabetes) (3.61 ± 0.31 to 2.41 ± 0.14, p<10- 5).

    “HOMA-IR from 3.61 ± 0.31 to 2.41 ± 0.14.”

    Human trialprediabetesHIMABERB®500 mg three times daily12 weeksn = 34

    Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

    BMC endocrine disorders

  4. Berberine decreases HOMA-IR in humans (mild metabolic disorders induced by olanzapine).

    “FPG, FPI, HOMA-IR, HbA1, TG, BMI, and WC were significantly lower in patients who received berberine compared to placebo after 12 weeks of treatment”

    Human trialmild metabolic disorders induced by olanzapine12 weeks

    Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine

    The American journal of Chinese medicine

  5. Berberine decreases HOMA-IR (-1.06(-1.51 –-0.61) vs -0.26(-0.72–0.20)).

    “In comparison with LSI alone, BBR exhibited extra decreases in body weight [-4.29(-5.04 –-3.54)kg vs -1.99(-2.76 –-1.23)kg, p<0.001], BMI [-1.51(-1.79 –-1.25)kg/m2 vs -0.72(-0.99 –-0.44) kg/m2, p<0.001], waist circumference[-4.84(-5.70 –-3.97)cm vs -2.14(-3.03 –-1.26)cm, p<0.001], HFC [-17.4(-20.8 –-14.0)% vs -11.4(-14.8 –-7.9)%, p = 0.008), 2h postload glucose [-2.19(-2.87 –-1.51)mmol/L vs -1.05(-1.73 –-0.37)mmol/L, p = 0.020), area under the OGTT curve [-6.14(-7.72 –-4.55) vs -3.33(-4.93 –-1.73), p = 0.015], HOMA-IR [-1.06(-1.51 –-0.61) vs -0.26(-0.72–0.20), p = 0.014], serum cholesterol [-0.52(-0.71 –-0.33)mmol/L vs -0.12(-0.31–0.07)mmol/L, p = 0.004], APO-B [-0.12(-0.16 –-0.08)g/L vs -0.05(-0.09–0.01)g/L, p = 0.022] and triglycerides [-0.45(-0.68 –-0.23)mmol/L vs -0.02(-0.24–0.21)mmol/L, p = 0.007], showing clearly a significant benefit of BBR in metabolism”

    Human trial16-weeksn = 184

    Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

    PloS one

  6. Berberine decreases HOMA-IR in humans (plus LSI) (p<0.05).

    “better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05).”

    Human trialplus LSI0.5g tid16 weeks

    Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

    PloS one

  7. Berberine decreases HOMA-IR in humans (compared with placebo in infertile women with PCOS undergoing IVF treatment).

    “greater reductions in total testosterone, free androgen index, fasting glucose, fasting insulin and HOMA-IR, and increases in SHBG, were observed in the berberine and metformin groups”

    Human trialcompared with placebo in infertile women with PCOS undergoing IVF treatmenttablets3 monthsfemalesn = 150

    The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment

    Clinical endocrinology

  8. Berberine decreases HOMA-IR in humans (poorly controlled type 2 diabetes mellitus) (reduced by 44.7% (P<.001)).

    “homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively”

    Human trialpoorly controlled type 2 diabetes mellitus3 monthsn = 48

    Efficacy of berberine in patients with type 2 diabetes mellitus

    Metabolism: clinical and experimental

  9. Berberine decreases HOMA-IR in humans (non-alcoholic fatty liver disease) (SMD = -1.56, 95% CI [-2.54, -0.58]).

    “HOMA-IR (SMD = - 1.56, 95% CI [- 2.54, - 0.58], P = 0.002)”

    Reviewnon-alcoholic fatty liver disease

    The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review

    Journal of translational medicine

  10. Berberine decreases HOMA-IR in humans (-0.85, 95% CI -1.16 to -0.53).

    “HOMA-IR (-0.85, 95% CI -1.16 to -0.53,12 studies, n = 1065)”

    Reviewn = 1,065

    Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

    The Journal of nutrition

All 11

More on HOMA-IR

Cellular senescence

downin mice4downin cells2downin human cells1downin rat cells1+1

8 studies
  1. Berberine inhibits cellular senescence in cells (irradiated intestinal epithelial cells).

    “inhibits radiation-induced cellular senescence and SASP in vitro”

    Cellsirradiated intestinal epithelial cellsintestinal epithelial cells

    Berberine alleviates radiation-induced intestinal injury by inhibiting cellular senescence

    Radiation oncology (London, England)

  2. Berberine decreases cellular senescence in mice (radiation-induced intestinal injury).

    “BBR can alleviate radiation-induced DNA damage and senescence in mouse intestines”

    Animalsradiation-induced intestinal injuryintestine

    Berberine alleviates radiation-induced intestinal injury by inhibiting cellular senescence

    Radiation oncology (London, England)

  3. Berberine decreases cellular senescence in doxorubicin-induced senescent cells and natural aging mice.

    “a potential candidate for attenuating hepatic senescence”

    Animalsin doxorubicin-induced senescent cells and natural aging miceliver

    M6PR upregulation by berberine attenuates hepatic senescence via sorting STING into endosome for degradation

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  4. Berberine decreases cellular senescence in mice.

    “BBR alleviates the aging of adipose tissue and adipose derived stem cells (ADSCs), thereby decreasing the secretion of senescence-associated secretory phenotype (SASP).”

    Animalsadipose tissue

    Berberine inhibits metastasis of ovarian cancer by blocking lipid metabolism, alleviating aging of adipose tissue and increasing tumor infiltrating immune cells

    Translational oncology

  5. Berberine protects against cellular senescence in rat cells (doxorubicin-induced senescence in H9c2 cells).

    “BBR protected H9c2 cells against DOX-induced senescence.”

    Cellsdoxorubicin-induced senescence in H9c2 cells

    Berberine exerts protective effects on cardiac senescence by regulating the Klotho/SIRT1 signaling pathway

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

  6. Berberine decreases cellular senescence in mice (D-galactose-induced senescence).

    “BBR down-regulated the expression of REDD1 to decrease intracellular ROS content, attenuating DG-induced senescence in vitro and in vivo.”

    AnimalsD-galactose-induced senescenceretinal pigment epithelium

    Berberine-mediated REDD1 down-regulation ameliorates senescence of retinal pigment epithelium by interrupting the ROS-DDR positive feedback loop

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  7. Berberine decreases cellular senescence in human cells (cigarette smoke-induced).

    “in 16HBE cells, berberine-LCNs inhibited the cigarette smoke-induced senescence as revealed by X-gal staining, gene expression of CDKN1A (p21)”

    Cellscigarette smoke-induced16HBE

    Attenuation of Cigarette-Smoke-Induced Oxidative Stress, Senescence, and Inflammation by Berberine-Loaded Liquid Crystalline Nanoparticles: In Vitro Study in 16HBE and RAW264.7 Cells

    Antioxidants (Basel, Switzerland)

  8. Berberine decreases cellular senescence.

    “and attenuate premature cellular senescence”

    Review

    Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation

    Aging and disease

  9. Berberine decreases cellular senescence in cells (mitoxantrone-induced premature senescence).

    “All these markers of senescence were distinctly diminished, in a concentration-dependent manner, by Berberine.”

    Cellsmitoxantrone-induced premature senescence

    Berberine suppresses gero-conversion from cell cycle arrest to senescence

    Aging

More on Cellular senescence

AMPK signaling

upin reviews7upin humans1

8 studies
  1. Berberine activates AMPK signaling.

    “Berberine activates AMP-activated protein kinase (AMPK) via mild mitochondrial complex I inhibition”

    Review

    Berberine as a multi-hallmark modulator of aging: From AMPK and mitophagy to inflammaging and the SASP

    Fitoterapia

  2. Berberine activates AMPK signaling in humans.

    “Key nutraceuticals-phytosterols, omega-3 fatty acids, and berberine-demonstrate clinically meaningful effects through micellar competition, inflammation-resolving lipid mediators, and AMPK activation, respectively.”

    Review

    Non-Pharmacological Strategies in Atherosclerotic Cardiovascular Disease: From Molecular Mechanisms to Clinical Integration

    Biomedicines

  3. Berberine activates AMPK signaling.

    “exemplified by berberine via AMPK, curcumin via NF-κB, and resveratrol via SIRT1”

    Review

    Neuro-metabolic ageing drives diabetes-associated neurodegeneration: A geroscience and network pharmacology perspective

    Ageing research reviews

  4. Berberine activates AMPK signaling.

    “BBR, by contrast, primarily activates AMPK (AMP-activated protein kinase)”

    Review

    Mitochondrial Health Through Nicotinamide Riboside and Berberine: Shared Pathways and Therapeutic Potential

    International journal of molecular sciences

  5. Berberine activates AMPK signaling.

    “berberine induces glucose metabolism by activating AMPK signaling”

    Review

    Addressing the preventive and therapeutic perspective of berberine against diabetes

    Heliyon

  6. Berberine activates AMPK signaling.

    “activating the AMPK pathway”

    Review

    Berberine and Its Study as an Antidiabetic Compound

    Biology

  7. Berberine activates AMPK signaling.

    “The activity of AMPK can be stimulated with the phytochemical berberine.”

    Review

    Nutraceutical and Dietary Strategies for Up-Regulating Macroautophagy

    International journal of molecular sciences

  8. Berberine activates AMPK signaling.

    “via anti-oxidation and AMPK cellular kinase activation”

    Review

    Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation

    Aging and disease

More on AMPK signaling

HbA1c

downin humans7

7 studies
  1. Berberine decreases HbA1c in humans (−0.99 [−1.16, −0.83]% vs −0.59 [−0.75, −0.44]%).

    “Thus, BBR and BBR with probiotics were both superior to the Plac in lowering HbA1c, but Prob was not.”

    Human trial12 weeksn = 409

    Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

    Nature communications

  2. Berberine decreases HbA1c in humans (newly diagnosed T2D) (least-squares mean [95% CI], -0.99[-1.16, -0.83]% vs -0.59[-0.75, -0.44]%).

    “BBR-alone group (-0.99[-1.16, -0.83]%) were significantly greater than that in the placebo and probiotics-alone groups (-0.59[-0.75, -0.44]%, -0.53[-0.68, -0.37]%, P < 0.001).”

    Human trialnewly diagnosed T2D12-weekn = 409

    Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

    Nature communications

  3. Berberine decreases HbA1c in humans (newly diagnosed type 2 diabetes mellitus) (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01).

    “Significant decreases in hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01)”

    Human trialnewly diagnosed type 2 diabetes mellitus0.5 g 3 times a day3 monthsn = 36

    Efficacy of berberine in patients with type 2 diabetes mellitus

    Metabolism: clinical and experimental

  4. Berberine decreases HbA1c in type 2 diabetic patients with dyslipidemia (HbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%, P < 0.0001 vs placebo).

    “fasting and postload plasma glucose decreased from 7.0 +/- 0.8 to 5.6 +/- 0.9 and from 12.0 +/- 2.7 to 8.9 +/- 2.8 mm/liter, HbA1c from 7.5 +/- 1.0% to 6.6 +/- 0.7%”

    Human trialin type 2 diabetic patients with dyslipidemia1.0 g daily3 monthsn = 116

    Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine

    The Journal of clinical endocrinology and metabolism

  5. Berberine decreases HbA1c in metabolic disorders (ESWMD: -0.57; 95% CI: -0.68 to -0.46).

    “reducing fasting blood glucose (FBG) (ESWMD: -0.77; 95% CI: -0.90 to -0.63, and ESSMD: -0.65; 95% CI: -0.83 to -0.47), hemoglobin A1C (HbA1C) (ESWMD: -0.57; 95% CI: -0.68 to -0.46)”

    Reviewin metabolic disorders

    The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials

    Clinical therapeutics

  6. Berberine decreases HbA1c in humans (-4.48 mmol/mol, 95% CI -6.53 to -2.44).

    “HbA1c (-4.48 mmol/mol, 95% CI -6.53 to -2.44, 7 studies, n = 756)”

    Reviewn = 756

    Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

    The Journal of nutrition

  7. Berberine decreases HbA1c in humans (applied alone or with standard diabetic therapies versus the control group) (MD = -0.73, 95% CI (-0.97, -0.51)).

    “Analysis of berberine applied alone or with standard diabetic therapies versus the control group revealed significant reductions in HbA1c (MD = -0.73; 95% CI (-0.97, -0.51))”

    Reviewapplied alone or with standard diabetic therapies versus the control group

    The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Oxidative medicine and cellular longevity

  8. Berberine decreases HbA1c in humans (type 2 diabetes mellitus) (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15).

    “Berberine treatment was associated with a better reduction on FPG (WMD = -0.54 mmol/L, 95% CI: -0.77 to -0.30), PPG (WMD = -0.94 mmol/L, 95% CI: -1.27 to -0.61), and HbA1c (WMD = -0.54 mmol/L, 95% CI: -0.93 to -0.15) than control groups”

    Reviewtype 2 diabetes mellitus

    Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis

    Endocrine journal

More on HbA1c

Lifespan

upin worms3upin flies2upin mice1upin reviews1+27% mean lifespan

7 studies
  1. Berberine extends lifespan.

    “to slow aging, and to extend lifespans and health spans of animals”

    Review

    Berberine induces pleiotropic beneficial effects via hormesis

    Pharmacological research

  2. Berberine extends lifespan in worms (+27% mean lifespan).

    “berberine extended the mean lifespan of wild-type worms by 27%”

    Model organisms

    Berberine Extends Lifespan in C. elegans Through Multi-Target Synergistic Antioxidant Effects

    Antioxidants (Basel, Switzerland)

  3. Berberine extends lifespan in worms.

    “five compounds (all-trans retinoic acid, berberine, fisetin, propranolol, and ritonavir) extended lifespan in Caenorhabditis elegans.”

    Model organisms

    Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically-diverse Caenorhabditis nematodes

    eLifePreprint

  4. Berberine extends lifespan in worms.

    “We find that 10 μM berberine significantly extends healthy lifespan in wild type C. elegans.”

    Model organisms10 μM

    Berberine extends healthspan and delays neurodegenerative diseases in Caenorhabditis elegans through ROS-dependent PMK-1/SKN-1 activation

    Archives of gerontology and geriatrics

  5. Berberine extends lifespan in mice (chemotherapy-treated) (~52%).

    “BBR extended the lifespan of chemotherapy-treated mice and naturally aged mice by ~52% and ~16.49%, respectively.”

    Animalschemotherapy-treated

    Berberine ameliorates cellular senescence and extends the lifespan of mice via regulating p16 and cyclin protein expression

    Aging cell

  6. Berberine extends lifespan in flies.

    “berberine has recently been reported to expand life span in Drosophila melanogaster”

    Review

    Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation

    Aging and disease

  7. Berberine extends lifespan in flies (wild-type flies).

    “The results of our study showed that Berberine extended mean, median and maximum life span of female flies.”

    Model organismswild-type fliesfemales

    Berberine Prolongs Life Span and Stimulates Locomotor Activity of Drosophila melanogaster

    American journal of plant sciences

C-reactive protein

downin humans6

6 studies
  1. Berberine decreases C-reactive protein in humans (versus placebo) (-0.072 mg/dL [95% CI, -0.140 to -0.004]).

    “high-sensitivity C-reactive protein (hs-CRP) (-0.072 [95% CI, -0.140 to -0.004] mg/dL) vs placebo”

    Human trialversus placebo1 g/d6 monthsn = 337

    Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial

    JAMA network open

  2. Berberine decreases C-reactive protein in humans (−0.072 [95% CI, −0.140 to −0.004] mg/dL).

    “berberine was associated with larger reductions in LDL-C (−7.72 [95% CI, −13.13 to −1.93] mg/dL; P =.008), apoB (−3.42 [95% CI, −6.33 to −0.51] mg/dL; P =.02; to convert to g/L, multiply by 0.01) and hs-CRP (−0.072 [95% CI, −0.140 to −0.004] mg/dL; P =.04) compared with placebo”

    Human trial6 monthsn = 337

    Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial

    JAMA network open

  3. Berberine decreases C-reactive protein in metabolic disorders (ESWMD: -0.62; 95% CI: -0.74 to -0.50).

    “C-reactive protein (CRP) (ESWMD: -0.62; 95% CI: -0.74 to -0.50, and ESSMD: -1.70; 95% CI: -2.21 to -1.19)”

    Reviewin metabolic disorders

    The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials

    Clinical therapeutics

  4. Berberine decreases C-reactive protein in adults (-1.33 mg/L).

    “CRP levels (-1.33 mg/L)”

    Reviewin adultsn = 1,600

    Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials

    Phytotherapy research : PTR

  5. Berberine decreases C-reactive protein in patients with metabolic syndrome and related disorders (SMD = -1.54, 95% CI -1.86, -1.22, p < 0.05).

    “Pooled estimates showed that the use of berberine could significantly reduce the concentration level of C-reactive protein (CRP) [standardized mean difference (SMD) = - 1.54, 95% confidence intervals (CI) - 1.86, - 1.22, p < 0.05]”

    Reviewin patients with metabolic syndrome and related disordersn = 4,616

    The effects of berberine on inflammatory markers in Chinese patients with metabolic syndrome and related disorders: a meta‑analysis of randomized controlled trials

    Inflammopharmacology

  6. Berberine decreases C-reactive protein in humans (WMD = -0.42 mg/L, 95% CI -0.82, -0.03).

    “C-reactive protein (CRP) concentrations (WMD = -0.42 mg/L, 95% CI -0.82, -0.03, P = 0.034)”

    Review

    The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials

    Clinical nutrition ESPEN

  7. Berberine decreases C-reactive protein in humans (MD -0.64 mg/L, 95% CI -0.67 to -0.61, P < 0.001).

    “serum levels of CRP were decreased after BER supplementation (MD:-0.64 mg/L, 95% CI(-0.67 to -0.61) P < 0.001)”

    Review

    Effect of Berberine on C-reactive protein: A systematic review and meta-analysis of randomized controlled trials

    Complementary therapies in medicine

More on C-reactive protein

Triglyceride

downin humans6

6 studies
  1. Berberine decreases triglyceride in humans (newly diagnosed type 2 diabetes mellitus) (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05).

    “plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05) were observed in the berberine group”

    Human trialnewly diagnosed type 2 diabetes mellitus0.5 g 3 times a day3 monthsn = 36

    Efficacy of berberine in patients with type 2 diabetes mellitus

    Metabolism: clinical and experimental

  2. Berberine decreases triglyceride in humans (non-alcoholic fatty liver disease) (SMD = -0.59, 95% CI [-0.86, -0.31]).

    “TG (SMD = - 0.59, 95% CI [- 0.86, - 0.31], P < 0.0001)”

    Reviewnon-alcoholic fatty liver disease

    The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review

    Journal of translational medicine

  3. Berberine decreases triglyceride in humans (-0.34 mmol/L (95% CI -0.46 to -0.23)).

    “triglycerides (- 0.34 mmol/L, 95% CI - 0.46 to - 0.23, 18 studies, n = 1661)”

    Review4 to 24 weeksn = 1,661

    Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Drugs

  4. Berberine decreases triglyceride in humans (applied alone or with standard diabetic therapies versus the control group) (MD = -0.5, 95% CI (-0.61, -0.39)).

    “Lipid metabolisms were also ameliorated via the reduction of TG (MD = -0.5, 95% CI (-0.61, -0.39))”

    Reviewapplied alone or with standard diabetic therapies versus the control group

    The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Oxidative medicine and cellular longevity

  5. Berberine decreases triglyceride in humans (compared with simvastatin) (MD=-0.37, 95% CI: -0.66, -0.07, P=0.02).

    “Compared with the simvastatin group, berberine was effective only in reducing the level of triglyceride ( MD=-0.37 , 95% CI: - 0.66, - 0.07, P=0.02 ).”

    Reviewcompared with simvastatin

    Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

    The American journal of Chinese medicine

  6. Berberine decreases triglyceride in humans (hyperlipidemia and other dyslipidemias) (reductions ranging from approximately 25 to 55 mg/dL).

    “majority of evaluated articles consistently suggest that berberine has a beneficial effect on low-density lipoprotein (reductions ranging from approximately 20 to 50 mg/dL) and triglycerides (reductions ranging from approximately 25 to 55 mg/dL).”

    Reviewhyperlipidemia and other dyslipidemias

    Efficacy of Berberine Alone and in Combination for the Treatment of Hyperlipidemia: A Systematic Review

    Journal of evidence-based complementary & alternative medicine

More on Triglyceride

HDL cholesterol

upin humans6+6.6% increase

6 studies
  1. Berberine increases HDL cholesterol in humans (compared with placebo).

    “Berberine reduced total cholesterol, triglycerides and LDL cholesterol and increased HDL cholesterol after 3 months from randomization and compared with placebo.”

    Human trialcompared with placebo500 mg twice a day3 months

    Effects of berberine on lipid profile in subjects with low cardiovascular risk

    Expert opinion on biological therapy

  2. Berberine increases HDL cholesterol in humans (new diagnosed type 2 diabetes combining nonalcoholic fatty liver disease).

    “however, HDL-L significantly increased (P<0.05).”

    Human trialnew diagnosed type 2 diabetes combining nonalcoholic fatty liver disease12 weeks

    Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease

    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

  3. Berberine increases HDL cholesterol in humans (6.6% increase).

    “increased HDL (by 6.6% and 5.1%)”

    Human trial4 weeksn = 20

    Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents. A single-blind clinical investigation

    Arzneimittel-Forschung

  4. Berberine increases HDL cholesterol in women; sex-specific effect (0.11 mmol/L (95% CI 0.09 to 0.13)).

    “the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13)”

    Reviewin women; sex-specific effect4 to 24 weeksfemales

    Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Drugs

  5. Berberine increases HDL cholesterol in humans (alone or along with lipid lowing drugs in patients with dyslipidemia).

    “use berberine alone or along with lipid lowing drugs could reduce TC, TG, LDL-C levels and increased HDL-C levels with statistically significant difference”

    Reviewalone or along with lipid lowing drugs in patients with dyslipidemia

    Systematic review and Meta-analysis on efficacy and safety of berberine for dyslipidemia

    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica

  6. Berberine increases HDL cholesterol in humans (when used alone in patients with dyslipidaemias) (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001).

    “Berberine also increased the level of high-density lipoprotein cholesterol (HDL-C) when used alone (MD = 0.08 mmol/l 95% CI [0.03, 0.12], p = 0.001).”

    Reviewwhen used alone in patients with dyslipidaemias

    Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials

    Phytomedicine : international journal of phytotherapy and phytopharmacology

More on HDL cholesterol

Low-density lipoprotein cholesterol

downin humans5

5 studies
  1. Berberine decreases low-density lipoprotein cholesterol in humans (−7.72 [95% CI, −13.13 to −1.93] mg/dL).

    “berberine was associated with larger reductions in LDL-C (−7.72 [95% CI, −13.13 to −1.93] mg/dL; P =.008”

    Human trial6 monthsn = 337

    Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial

    JAMA network open

  2. Berberine decreases low-density lipoprotein cholesterol in humans (adjunctive treatment) (all p<0.05).

    “Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo.”

    Human trialadjunctive treatment900mg/day8 weeksn = 49

    The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial

    Psychiatry research

  3. Berberine decreases low-density lipoprotein cholesterol in women with PCOS and IR receiving compound cyproterone acetate (P<0.05).

    “total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDLC; P<0.05) as well as increase in high-density lipoprotein cholesterol (HDLC)”

    Human trialin women with PCOS and IR receiving compound cyproterone acetate3 monthsfemales

    A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome

    European journal of endocrinology

  4. Berberine decreases low-density lipoprotein cholesterol in humans (compared with placebo) (P<0.05).

    “berberine could significantly reduce the total cholesterol and low-density lipoprotein levels and elevate the high density lipoprotein level”

    Reviewcompared with placebo

    Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials

    The American journal of Chinese medicine

  5. Berberine decreases low-density lipoprotein cholesterol in humans (adults) (MD -0.65 mmol/L, 95% CI -0.76 to -0.54).

    “low-density lipoprotein cholesterol (mean difference - 0.65 mmol/L; 95 % confidence interval - 0.76 to - 0.54) levels”

    Reviewadultsn = 874

    The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials

    Planta medica

More on Low-density lipoprotein cholesterol

Fasting blood glucose

downin humans3no changein humans1

4 studies
  1. Berberine decreases fasting blood glucose in humans (5.33 ± 0.28 vs 6.16 ± 0.44 mmol/L).

    “FPG after 84 days was significantly lower in the treatment group than in the control group, with a mean FPG of 5.33 ± 0.28 mmol/L for the treatment group and 6.16 ± 0.44 mmol/L for the control group (p<10− 5).”

    Human trial84 daysn = 34

    Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

    BMC endocrine disorders

  2. Berberine decreases fasting blood glucose in humans (prediabetes) (p<10- 5).

    “Significant decreases in all markers of glycemic control were observed in the treatment group at intermediate time points and the endpoint of the study compared to baseline levels and to the control group.”

    Human trialprediabetesHIMABERB®500 mg three times daily12 weeksn = 34

    Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial

    BMC endocrine disorders

  3. Berberine showed no clear effect on fasting blood glucose.

    “These findings led us to conclude that BBR significantly increases insulin secretion under hyperglycemic conditions but does not affect basal glucose levels in humans.”

    Human trial160 minmalesn = 15

    Berberine is an insulin secretagogue targeting the KCNH6 potassium channel

    Nature communications

  4. Berberine decreases fasting blood glucose in humans (type 2 diabetes mellitus).

    “BBR significantly lowered fasting blood glucose (FBG), hemoglobin A(1c), triglyceride, and insulin levels in patients with type 2 diabetes mellitus (T2DM).”

    Human trialtype 2 diabetes mellitus

    Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression

    Metabolism: clinical and experimental

  5. Berberine decreases fasting blood glucose in metabolic disorders (ESWMD: -0.77; 95% CI: -0.90 to -0.63).

    “BBR supplementation was effective in reducing fasting blood glucose (FBG)”

    Reviewin metabolic disorders

    The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials

    Clinical therapeutics

More on Fasting blood glucose

Blood pressure

no changein humans2downin humans2downin reviews1

4 studies
  1. Berberine showed no clear effect on blood pressure in humans.

    “Changes in triglycerides, thromboxane A2, blood pressure, body mass index and waist-hip ratio after the intervention did not differ between the berberine and placebo groups.”

    Human trial500 mg orally, twice a day12 weeksmalesn = 80

    Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial

    Nutrients

  2. Berberine decreases blood pressure.

    “lower blood pressure”

    Review

    Thinking About Berberine

    Integrative medicine (Encinitas, Calif.)

  3. Berberine decreases blood pressure in humans (compared to placebo) (-11.80 [-18.73, -4.87] mmHg systolic).

    “A proprietary nutraceutical containing berberine as one of its ingredients was in one study significantly effective at reducing blood pressure compared to placebo”

    Reviewcompared to placeboproprietary nutraceutical containing berberine as one of its ingredients

    Berberine for the treatment of hypertension: A systematic review

    Complementary therapies in clinical practice

  4. Berberine showed no clear effect on blood pressure in humans (compared to amlodipine alone).

    “Berberine plus amlodipine was not significantly better than amlodipine alone at reducing systolic and diastolic blood pressure.”

    Reviewcompared to amlodipine alone

    Berberine for the treatment of hypertension: A systematic review

    Complementary therapies in clinical practice

  5. Berberine decreases blood pressure in humans with lifestyle intervention or combined with oral hypotensor.

    “berberine with lifestyle intervention tended to lower the level of blood pressure more than the lifestyle intervention alone or placebo did”

    Reviewwith lifestyle intervention or combined with oral hypotensor

    Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension

    Journal of ethnopharmacology

More on Blood pressure

All 210

What is berberine linked with?

15

Studies link berberine with 15 measures, among them colorectal adenoma recurrence, body mass index and microbiome composition.

Colorectal adenoma recurrence

downin humans2RR 0.77

2 studies
  1. Berberine lowers the risk of colorectal adenoma recurrence in humans after complete polypectomy of colorectal adenomas (RR 0.77 (95% CI 0.66-0.91), 36% vs 47%).

    “155 (36%) participants in the berberine group and 216 (47%) in the placebo group were found to have recurrent adenoma during follow-up (unadjusted relative risk ratio for recurrence 0·77, 95% CI 0·66-0·91; p=0·001).”

    Human trialafter complete polypectomy of colorectal adenomas0.3 g twice dailyup to 2 years

    Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study

    The lancet. Gastroenterology & hepatology

  2. Berberine lowers the risk of colorectal adenoma recurrence in humans.

    “Clinical trials indicate that BBR reduces the recurrence of colorectal adenomas”

    Review

    Berberine's impact on health: Comprehensive biological, pharmacological, and nutritional perspectives

    Metabolism open

More on Colorectal adenoma recurrence

Body mass index

downin humans1

1 study
  1. Berberine is associated with body mass index in humans (PCOS; within-group change).

    “In the berberine group, significant reductions were observed in BMI, fasting insulin, HOMA-IR, total cholesterol, triglycerides, and androstenedione.”

    HumansPCOS; within-group change6 monthsfemalesn = 28

    Comparative Effects of Myo-Inositol, Metformin, Berberine, and Combination Therapy on Metabolic, Anthropometric and Hormonal Parameters in Women with Polycystic Ovary Syndrome: A 6-Month Observational Cohort Study

    Journal of clinical medicine

Microbiome composition

mixedin humans1

1 study
  1. Berberine is associated with microbiome composition in diverse clinical populations.

    “Six of seven studies reported significant compositional shifts; the most extensively characterised changes-observed predominantly in T2DM populations-included enrichment of γ-Proteobacteria and depletion of butyrate-producing taxa”

    Reviewin diverse clinical populations

    The Integrative Role of Berberine in Gut Microbiota Modulation and Cardiometabolic Outcomes: A Systematic Review of Randomised Clinical Trials

    Nutrients

More on Microbiome composition

Visfatin binding

mixedin silico1

1 study
  1. Berberine is associated with visfatin binding in silico (molecular docking) (Binding free energy of -8.5 kcal/mol).

    “Berberine had a binding free energy of -8.5 kcal/mol.”

    In silicomolecular docking

    Organic Molecular Strategy to Prevent Diabetes: An In Silico Screening of Berberine and Biguanides as Visfatin Antagonists

    Research SquarePreprint

Cardiometabolic outcomes

mixedin reviews1

1 study
  1. Berberine is associated with cardiometabolic outcomes.

    “Positive study-level signals are summarized in the cardiometabolic outcome class, null signals in the contextual adjacent evidence, cardiometabolic, immune and inflammation outcome classes, and negative signals in the contextual adjacent evidence outcome class.”

    Review

    Hypothesis-Generating Brief: Berberine hydrochloride — full paper

    Preprint

insulin and IGF signaling

mixedin zebrafish1

1 study
  1. Berberine is associated with insulin and IGF signaling in zebrafish during tail fin fold regeneration after transection.

    “Berberine induced accelerated regeneration is associated with the involvement of Insulin, IGF, stress response, jak-stat, cytokine, and cellular reprogramming signaling pathways”

    Animalsduring tail fin fold regeneration after transectiontail fin0.01%4 hours post transection

    Transcriptome analysis of Berberine induced accelerated tail fin regeneration in Zebrafish larvae

    Gene expression patterns : GEP

JAK–STAT signaling

mixedin zebrafish1

1 study
  1. Berberine is associated with JAK–STAT signaling in zebrafish during tail fin fold regeneration after transection.

    “Berberine induced accelerated regeneration is associated with the involvement of Insulin, IGF, stress response, jak-stat, cytokine, and cellular reprogramming signaling pathways”

    Animalsduring tail fin fold regeneration after transectiontail fin0.01%4 hours post transection

    Transcriptome analysis of Berberine induced accelerated tail fin regeneration in Zebrafish larvae

    Gene expression patterns : GEP

More on JAK–STAT signaling

Neurodegenerative disease

downin worms1

1 study
  1. Berberine lowers the risk of neurodegenerative disease in worms.

    “berberine also delays neurodegenerative diseases such as Alzheimer's and polyglutamine diseases in a PMK-1/SKN-1dependent manner.”

    Model organisms

    Berberine extends healthspan and delays neurodegenerative diseases in Caenorhabditis elegans through ROS-dependent PMK-1/SKN-1 activation

    Archives of gerontology and geriatrics

More on Neurodegenerative disease

Bioavailability

downin reviews1

1 study
  1. Berberine is associated with bioavailability (< 1%).

    “factors such as poor solubility, low permeability, P-glycoprotein (P-gp) efflux, and hepatic-intestinal metabolism result in BBR having a low bioavailability (< 1%)”

    Review

    Research progress on pharmacological effects and bioavailability of berberine

    Naunyn-Schmiedeberg's archives of pharmacology

Adverse events

upin humans1RR 2.91

1 study
  1. Berberine raises the risk of adverse events in humans (versus placebo) (RR 2.91, 95% CI 1.24 to 6.85, p=0.01).

    “BBR had more adverse events than placebo (RR 2.91, 95% CI 1.24 to 6.85, p=0.01).”

    Reviewversus placebo

    Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis

    Journal of ethnopharmacology

Severe ovarian hyperstimulation syndrome

downin humans1

1 study
  1. Berberine lowers the risk of severe ovarian hyperstimulation syndrome in infertile women with PCOS undergoing IVF treatment.

    “reduced the incidence of severe ovarian hyperstimulation syndrome”

    Human trialin infertile women with PCOS undergoing IVF treatmenttablets3 monthsfemalesn = 150

    The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment

    Clinical endocrinology

More on Severe ovarian hyperstimulation syndrome

All 15

Has berberine been tested in people?

1 of 43 about aging

Yes: 89 trials and 3 observational studies in people have been published, and 43 trials are registered.

Every condition in trials

All 40

Stopped

  • NCT01697735TerminatedDyslipidemias

    Because of lack of participants and funds

Trial sponsors

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Berberine extends fly lifespan across independent labs, but fly and worm tests also show no clear lifespan effect; human trials report replicated LDL reductions. One registered trial concerns aging; 15 trials across all uses ended over a year ago without posted results or linked papers. The National Natural Science Foundation of China funds 87 findings; 16 of 335 findings have company-affiliated authors.

  2. Summary rewritten as its findings changed.

    As it read before

    Berberine extends worm lifespan; a mouse study reports improved healthspan, and a human trial reports fewer colorectal adenoma recurrences. Independent labs report lower human cholesterol and HOMA-IR, but cholesterol results disagree. No registered trials concern aging; across uses, 21 ended over a year ago without posted results or citing papers, and some authors work at companies.

  3. Summary rewritten as its findings changed.

    As it read before

    In male rats exposed to sevoflurane, one study shows berberine reduces brain apoptosis and elevates brain BDNF. Reviews report that it extends lifespan, elicits biphasic hormetic responses, activates AMPK signaling, and inhibits both mTOR and NF-κB signaling.

  4. Summary written from the findings.

Latest

Dec 2025: 3Jan 2026: 11Feb 2026: 4Mar 2026: 5Apr 2026: 1May 2026: 5Jun 2026: 2Jul 2026: 1Aug 2026: 5Sep 2026: 7Oct 2026: 4Nov 2026: 048 papers in 12 months

See all 246 papers on berberine